

NCI's Clinical Trials Cooperative Groups National Meetings Report

Summer 2012

In This Issue:

American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Pediatric Hematology/Oncology (ASPHO), ASCO Gastrointestinal Cancers Symposium, American Urological Association, International Cognition and Cancer Task Force Conference (ICCTF), and Others

Cooperative Group Abstracts:

- [Breast Cancer](#)
- [CNS Cancer](#)
- [Gastrointestinal Cancer](#)
- [Genitourinary Cancer](#)
- [Gynecologic Cancer](#)
- [Head and Neck Cancer](#)
- [Hematological Cancer](#)
- [Kidney Cancer](#)
- [Leukemia, Myelodysplasia, and Transplantation](#)
- [Lung Cancer](#)
- [Lymphoma and Plasma Cell Disorders](#)
- [Melanoma/Skin Cancers](#)
- [Other Cancer](#)

NCI/CTEP Abstracts & Activities:

- [DCTD/DCP Abstracts](#)
- [DCTD and DCP Activities](#)

The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

INT-0149

The addition of chemotherapy to radiation therapy doubled the median survival time for certain patients with an aggressive form of oligodendroglioma, a rare brain tumor. Patients in the study had anaplastic oligodendrogliomas, but only those whose tumors contained a genetic abnormality known as the 1p19q co-deletion experienced a benefit from adding chemotherapy to radiation.

ADV0912

Crizotinib was utilized in relapsed/refractory ALK-driven tumors, including anaplastic large cell lymphoma (ALCL) and neuroblastoma (NB), in a dose-escalation and pharmacokinetic phase 1 trial. Inhibition of ALK in pediatric patients with ALK-driven tumors occurs with minimal toxicity and is associated with high complete response rate (7/8) for ALCL. Complete responses were also observed in two patients with NB, one with documented ALK mutation.



Cooperative Group Abstracts

Breast Cancer

ACOSOG/Alliance

Hunt KK, McCall LM, Ballman KV, Boughey JC, Mittendorf EA, Cox C, Whitworth PW, Leitch AM, Beitsch PD, Giuliano AE: Factors Associated with Local-Regional Recurrence Following a Negative Sentinel Node Biopsy: Results of the ACOSOG Z0010 Trial. American Surgical Association, San Francisco, CA, Apr 2012.

<http://meeting.americansurgical.info/abstracts/2012/3.cgi>

Protocol(s): ACOSOG-Z0010

Le-Petross H, McCall LM, Hunt K, Mittendorf EA, Ahrendt GM, Wilke LG, Leitch M, Taback B, Boughey JC: Role of axillary ultrasound after neoadjuvant chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis (ACOSOG Z1071). J Clin Oncol 2012; 30(Suppl): Abst. 1107.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94506

Protocol(s): ACOSOG-Z1071

CALGB/Alliance

Klepkin H, Pitcher BN, Ballman KV, Kimmick GG, Kornblith AB, Cohen HJ, Hurria A, Winer EP, Hudis CA, Muss HB: Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC). J Clin Oncol 2012; 30(Suppl): Abst. 6015.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99035

Protocol(s): CALGB-49907

Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, Naughton MJ, Layman RM, Carey LA, Somer RA, Perez E, Hudis CA, Winer EP: CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2012; 30(Suppl): Abst. CRA1002.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99475

Other Participant(s): NCCTG/Alliance

Protocol(s): CALGB-40502

ECOG

Arteaga CL, Mayer IA, O'Neill A, Swaby RF, Alpaugh K, Yang XJ, Wagner LI, Meropol NJ, Saphner TJ, Jahanzeb M, Perez E, Lin NU, Sledge GW: A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105). J Clin Oncol 2012; 30(Suppl): Abst. 605.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101373

Protocol(s): E1105

Badve SS, Gray RJ, Baehner FL, Solin LJ, Butler S, Yoshizawa C, Shak S, Hughes LL, Page DL, Sledge GW, Davidson NE, Perez E, Ingle J, Woods WC, Sparano JA: Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. *J Clin Oncol* 2012; 30(Suppl): Abst. 1005.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98808

Protocol(s): E5194

Mendoza TR, Zhao F, Cleeland C, Wagner LI, Patrick-Miller LJ, Fisch MJ: Understanding the symptom experience of breast cancer outpatients: The validity and utility of the M.D. Anderson Symptom Inventory (MDASI). *J Clin Oncol* 2012; 30(Suppl): Abst. 9106.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97074

Protocol(s): E2Z02

Partridge AH, Sepucha K, O'Neill A, Miller KD, Motley C, Swaby RF, Schneider BP, Dang CT, Northfelt DW, Sledge GW: Does unblinding of treatment assignment impact participant perceptions in clinical trials? *J Clin Oncol* 2012; 30(Suppl): Abst. 6025.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101377

Protocol(s): E5103

Sparano JA, O'Neill A, Gray RJ, Perez E, Shulman LN, Martino S, Badve SS, Baehner FL, Childs BH, Yoshizawa CN, Rowley S, Davidson NE, Shak S, Goldstein LJ: 10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features. *J Clin Oncol* 2012; 30(Suppl): Abst. 1021.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94749

Protocol(s): E2197

Wagner LI, Gray RJ, Sledge GW, Whelan T, Hayes D, Geyer CE, Dees EC, Cella D, Sparano JA: Patient-reported cognitive impairments among women with breast cancer randomly assigned to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C+HT): Results from the Trial Assigning Individualized Options for Treatment (TAILORx). *J Clin Oncol* 2012; 30(Suppl): Abst. 9020.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99178

Other Participant(s): SWOG

Protocol(s): PACCT-1

Wagner LI, Gray RJ, Sledge GW, Whelan T, Zujewski J, Hayes DF, Geyer C, Dees EC, Sparano JA: Patient-reported cognitive impairments among women with breast cancer randomized to hormonal therapy alone versus chemotherapy followed by hormonal therapy: Results from the TAILORx trial (PACCT-1). International Cognition and Cancer Task Force Conference (ICCTF), Paris, France, Mar 2012. Abst. 56.

Other Participant(s): SWOG

Protocol(s): PACCT-1

Willis S, Miller KD, Young B, Perou CM, Hu Z, Sparano JA, Gray RJ, Sledge GW, Davidson NE, Leyland-Jones BR: Association of a compact 13-gene VEGF signature with OS in E2100. *J Clin Oncol* 2012; 30(Suppl): Abst. 1027.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98167

Protocol(s): E2100

NCCTG/Alliance

Sideras K, Moreno-Aspitia A, Tenglin RC, Liu H, Lingle WL, Reinholz MM, Halling KC, Chen B, Gross G, Mowat RB, Dakhil SR, Perez EA: Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer (N1031, Alliance). *J Clin Oncol* 2012; 30(Suppl): Abst. 1083.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96940

Protocol(s): N1031

Tan W, Allred JB, Moreno-Aspitia A, Northfelt DW, Ingle JN, Perez EA: Phase I study of panobinostat (LBH589) and letrozole in post-menopausal women with metastatic breast cancer. *J Clin Oncol* 2012; 30(Suppl): Abst. E13501.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95426

Protocol(s): N093B

NCIC Clinical Trials Group

Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE: Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. *J Clin Oncol* 2012; 30(Suppl): Abst. 524.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95125

Other Participant(s): NCCTG/Alliance

Protocol(s): NCIC-MA.27

Shepherd LE, Chapman J-AW, Ali SM, Zhu L, Leitzel K, Goss PE, Lipton A: Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. *J Clin Oncol* 2012; 30(Suppl): Abst. 501.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=93668

Other Participant(s): NCCTG/Alliance

Protocol(s): NCIC-MA.27

Vogl SE, Altwaairgi AK, Chapman J-AW, Zhu L, Shepherd LE, Goss PE: Characterization of patients who received further adjuvant endocrine therapy after 5 years of aromatase inhibitors (AIs): NCIC CTG MA 27. *J Clin Oncol* 2012; 30(Suppl): Abst. E11005.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95280

Protocol(s): NCIC-MA.27

NSABP

Chapman J-AW, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN: Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. *J Clin Oncol* 2012; 30(Suppl): Abst. 538.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94683

Protocol(s): NSABP-B-29

Cobleigh MA, Anderson SJ, Julian TB, Siziopikou KP, Arthur DW, Rabinovitch R, Zheng P, Mamounas EP, Luknic AM, Behrens RJ, Chu L, Leasure NC, Atkins JN, Polikoff J, Seay TE, Noyes RD, Stella PJ, McCaskill-Stevens WJ, Wolmark N: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx): NSABP B-43. J Clin Oncol 2012; 30(Suppl): Abst. TPS657.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96720

Protocol(s): NSABP-B-43

Fehrenbacher L, Jeong J-H, Rastogi P, Geyer CE, Paik S, Ganz PA, Land SR, Costantino JP, Swain SM, Mamounas EP, Wolmark N: NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancer. J Clin Oncol 2012; 30(Suppl): Abst. TPS1142.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94083

Protocol(s): NSABP-B-47

Swain SM, Tang G, Geyer CE, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Perez EA, Paik S, Costantino JP, Mamounas EP, Wolmark N: NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. J Clin Oncol 2012; 30(Suppl): Abst. LBA1000.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98794

Protocol(s): NSABP-B-38

Tanaka N, Jeong J-H, Gavin PG, Pogue-Geile KL, Paik S, Costantino JP: Graphical method to predict drug response using genomic biomarkers with nonlinear interaction effect. Proc Am Assoc Cancer Res 2012; 72(8 Suppl): Abst. 2711.

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/2711?sid=6f12db74-c432-4df8-8365-9cdcc7a94364

Protocol(s): NSABP-B-31

SWOG

Hershman D, Unger J, Crew K, Moinpour C, Minasian L, Hansen L, Lew D, O'Kane P, Wade J, Wong S, Hortobagyi G, Meyskens F, Albain K: SWOG S0715: Randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy. J Clin Oncol 2012; 30(Suppl): Abst. 9018.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95515

Protocol(s): S0715

CNS Cancer

NCCTG/Alliance

Laack NN, Galanis E, Leinweber C, Buckner JC, Giannini C, Geoffroy FJ, Jaeckle KA, Sarkaria JN: Phase I/randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study. *J Clin Oncol* 2012; 30(Suppl): Abst. 2032.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92558

Protocol(s): N0877

Lafky JM, Anderson SK, Morlan BW, Nelson GD, Carrero XW, Kumar S, Reynolds JT, Stella PJ, Dakhil SR, Loui WS, Alberts SR, Flynn PJ, Gross HM, Jaeckle KA, Buckner JC, Galanis E, Grothey A: Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib. *Proc Am Assoc Cancer Res* 2012; 72(8 Suppl): Abst. 5562.

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/5562?sid=84e7dba9-5fa1-422c-8343-ea933be7ba4c

Protocol(s): N054C, N0776

Ma D, Galanis E, Schiff D, Wu W, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Buckner JC, Sarkaria JN: NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial. *J Clin Oncol* 2012; 30(Suppl): Abst. 2031.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100091

Protocol(s): N057K

Wu W, Galanis E, Buckner J, Jaeckle K, Sargent D: Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials. *J Clin Oncol* 2012; 30(Suppl): Abst. 2004.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94341

Protocol(s): Multiple Trials

RTOG

Cairncross JG, Wang M, Shaw EG, Jenkins RB, Scheithauer BW, Brachman D, Buckner JC, Fink KL, Souhami L, Laperriere N, Curra WJ, Mehta MP: Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. *J Clin Oncol* 2012; 30(Suppl): Abst. 2008b.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91431

Other Participant(s): NCCTG/Alliance, SWOG

Protocol(s): INT-0149

Ratai E, Zhang Z, Snyder B, Yeh M, L'Heureux D, Downs J, Boxerman J, Safriel Y, Gilbert M, Barboriak D, Sorensen G: MR spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: ACRIN 6677 / RTOG 0625. *International Society for Magnetic Resonance in Medicine (ISMRM), Melbourne, Australia, May 2012*. Abst. 3178.

http://www.ismrm.org/12/ep_05.htm

Other Participant(s): ACRIN

Protocol(s): RTOG-0625

Gastrointestinal Cancer

ACOSOG/Alliance

Reed CE, Decker PA, Schefter TE, Meyers BF, Ferguson MK, Oeltjen AR, Putnam JB Jr., Cassivi SD, Lockhart AC: A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). *J Clin Oncol* 2012; 30(Suppl): Abst. 4062.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92693

Protocol(s): ACOSOG-Z4051

CALGB/Alliance

Hasson RM, Niedzwiecki D, Bertagnolli MM: A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803. *Proc Am Assoc Cancer Res* 2012; 72(8 Suppl): Abst. 4514.

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/4514?sid=741cde25-e610-40dc-8004-f71059c2af51

Protocol(s): C89803

Warren RS, Atreya C, Niedzwiecki D, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Donner DB, Ye C, Weinberg VK, Saltz LB, Bertagnolli MM: A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803. *J Clin Oncol* 2012; 30(Suppl): Abst. 452.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88492

Protocol(s): C89803

ECOG

Bates DO, Catalano P, Symonds K, Varey AH, Ramani P, O'Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ: Predictive value of the antiangiogenic VEGF splice variant expression for bevacizumab efficacy in the phase III trial of bevacizumab and FOLFOX4 versus FOLFOX4 in previously treated patients with advanced colorectal cancer (ECOG E3200T2). *J Clin Oncol* 2012; 30(Suppl): Abst. 545.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87848

Protocol(s): E3200

Garg MK, Lee JY, Catalano P, Henry DH, Cooley TP, Ratner L, Wachsman W, Aboulafia DM, Benson AB, Palefsky J, Whittington R, Mitsuyasu RT, Sparano JA: Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results. *J Clin Oncol* 2012; 30(Suppl): Abst. 4030.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95820

Protocol(s): E3205

Kleinberg LR, Catalano P, Forastiere AA, Keller SM, Anne PR, Benson AB: Long-term survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. *J Clin Oncol* 2012; 30(Suppl 4): Abst. 69.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88641

Protocol(s): E1201

NCCTG/Alliance

Kim GP, Foster NR, Haddock MG, Bollinger JW, Dakhil SR, Behrens RJ, Flynn PJ, Steen PD, Bury MJ, Stella PH, Alberts SR: North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer. *J Clin Oncol* 2012; 30(Suppl): Abst. 271.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88540

Protocol(s): N064A

McWilliams RR, Mahoney MR, Sargent DJ, Nelson GD, Sinicrope F, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Alberts SR: A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. *J Clin Oncol* 2012; 30(Suppl 4): Abst. 446.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88834

Protocol(s): N0147

Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Newcomb PA, Alberts SR: Smoking status and prognosis in patients with stage III colon cancer: A correlative analysis of NCCTG phase III trial N0147. *J Clin Oncol* 2012; 30(Suppl): Abst. 3526.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96778

Protocol(s): N0147

Sha D, Lee A, Shi Q, Steven AR, Sargent DJ, Sinicrope FA, Diasio RB: Association study of the let-7 microRNA-binding site polymorphism in 3'-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147. *J Clin Oncol* 2012; 30(Suppl): Abst. 3564.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96648

Protocol(s): N0147

Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson G, Sargent DJ, Alberts SR: Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX with or without cetuximab: NCCTG N0147. *J Clin Oncol* 2012; 30(Suppl): Abst. 3514.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92948

Protocol(s): N0147

Sloan JA, Shi Q, Lee A, Diasio RB, Pavey ES, Sargent DJ, Goldberg RM, Sinicrope FA, Mahoney MR, Alberts SR: Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). *J Clin Oncol* 2012; 30(Suppl): Abst. 3617.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101328

Protocol(s): N0147

NSABP

Boman BM, Bandos H, Wickerham DL, Petrelli NJ, O'Connell MJ, Wolmark N: Statin polyp prevention trial in patients with resected colon cancer: NSABP protocol P-5. J Clin Oncol 2012; 30(Suppl): Abst. TPS1615.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98385

Protocol(s): NSABP-P-05

Ganz PA, Lopa SH, Yothers G, Ko CY, Arora A, Atkins JN, Bahary N, Soori GH, Robertson JM, Eakle JF, Marchello BT, Wozniak TF, Wolmark N: Comparative effectiveness of sphincter-sparing surgery (SSS) versus abdomino-perineal resection (APR) in rectal cancer: Patient-reported outcomes (PROs) from NSABP R-04. J Clin Oncol 2012; 30(Suppl): Abst. 3545.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94535

Protocol(s): NSABP-R-04

Haller DG, O'Connell M, Cartwright TH, Twelves C, McKenna E, Sun W, Saif WM, Lee LF, Yothers G, Schmoll H-J: Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials. J Clin Oncol 2012; 30(Suppl): Abst. 3522.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97548

Protocol(s): NSABP-C-08

O'Connell MJ, Lee M, Lopatin M, Yothers G, Clark-Langone K, Millward C, Paik S, Sharif S, Shak S, Wolmark N: Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). J Clin Oncol 2012; 30(Suppl): Abst. 3512.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99494

Protocol(s): NSABP-C-07

Sun W, Schmoll H-J, O'Connell MJ, Cartwright TH, Twelves C, McKenna E, Saif WM, Lee LF, Yothers G, Haller DG: Comparative evaluation of capecitabine or infusional leucovorin/5-fluorouracil (LV/5-FU) with or without oxaliplatin (Ox) for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials. J Clin Oncol 2012; 30(Suppl): Abst. 3525.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99870

Protocol(s): NSABP-C-08

Twelves C, Schmoll H-J, O'Connell M, Cartwright TH, McKenna E, Sun W, Saif WM, Lee LF, Yothers G, Haller DG: Effect of oxaliplatin-based adjuvant therapy on post-relapse survival (PRS) in patients with stage III colon cancer: A pooled analysis of individual patient data from four randomized controlled trials. J Clin Oncol 2012; 30(Suppl): Abst. 3523.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97638

Protocol(s): NSABP-C-08

Yothers G, Ganz PA, Lopa SH, Ko C, Wickerham DL, Wolmark N: Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04. J Clin Oncol 2012; 30(Suppl 4): Abst. 391.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88085

Protocol(s): NSABP-R-04

RTOG

Farrell J, Wong J, Moughan J, Regine W, Schaefer P, Benson A Macdonald J, Liu X, Yen Y, Lai R, Zheng Z, Bepler G, Elsaleh H: Predictive Markers of Gemcitabine Treatment Response in Pancreas Cancer: A Pharmacogenomic Pathway Approach. *Gastroenterology* 2012; 142(5 (Suppl. 1)): pg. S-113.

<http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508512604247.pdf>

Other Participant(s): SWOG

Protocol(s): RTOG-97-04

SWOG

El-Khoueiry A, Rankin C, Iqbal S, Micetich K, Kayaleh O, Lenz H, Blanke C: SWOG 0941: A phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma. *J Clin Oncol* 2012; 30(Suppl): Abst. 4113.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100314

Protocol(s): S0941

Gordon MA, Gundacker H, Benedetti J, Macdonald J, Baranda J, Levin W, Wick N, Blanke C, Elatre W, Weng P, Zhou J-Y, Lenz H, Press M: Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. *J Clin Oncol* 2012; 30(Suppl): Abst. 4010.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92136

Protocol(s): INT-0116

Klein EA, Thompson IM, Tangen CM, Crowley J, Lucia MS, Goodman PJ, Minasian L, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman S, Goodman G, Meyskens F, Baker L: Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *J Clin Oncol* 2012; 30(Suppl 4): Abst. 7.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID=89317

Protocol(s): S0000

Labonte M, Goldman B, Zhang W, Blanke CD, Philip PA, Wong R, O'Reilly EM, Benedetti JK, Lenz HJ: Use of EGF A61G polymorphism to predict overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205). *J Clin Oncol* 2012; 30(Suppl): Abst. 203.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87914

Protocol(s): S0205

Philip PA, Goldman B, Ramanathan R, Lenz H, Lowy A, Whitehead R, Iqbal S, Gaur R, Benedetti J, Blanke CD: Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727). *J Clin Oncol* 2012; 30(Suppl): Abst. 4019.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98448

Protocol(s): S0727

Philip PA, Goldman B, Ramanathan R, Lenz H, Lowy A, Whitehead R, Iqbal S, Gaur R, Benedetti J, Blanke CD: Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727). *J Clin Oncol* 2012; 30(Suppl 4): Abst. 198.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87986

Protocol(s): S0727

Genitourinary Cancer

CALGB/Alliance

Apolo AB, Philips GK, Ostrovnaya I, Rosenberg JE, Milowsky M, Iasonos A, Small EJ, Bajorin DF, Halabi S: External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. *J Clin Oncol* 2012; 30(Suppl): Abst. 4592.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100038

Protocol(s): CALGB-90102

Halabi S, Kelly WK, Kaplan EB, Small EJ: Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol* 2012; 30(Suppl 5): Abst. 200.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID=89569

Protocol(s): CALGB-90401

Harzstark AL, Halabi S, Kelly WK, Morris MJ, Febbo PG, Small EJ: Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy. *J Clin Oncol* 2012; 30(Suppl 5): Abst. 129.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID=88999

Protocol(s): CALGB-90401

Kelly W, Halabi S, Carducci M, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk PJ, Small EJ: Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). *J Clin Oncol* 2012; 30(Suppl): Abst. 4655.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96038

Protocol(s): CALGB-90401

Small EJ, Halabi S, Carducci M, Ryan CJ, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk PJ, Kelly W: The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401). *J Clin Oncol* 2012; 30(Suppl): Abst. 4667.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100283

Protocol(s): CALGB-90401

NCIC Clinical Trials Group

Mason MD, Parulekar W, Sydes MR, Parmar M, Anderson J, Barber J, Brundage MD, Cowan R, Gospodarowicz MK, Hayter C, Hetherington J, Hiltz AC, Kirkbride P, Kostashuk E, Sanders K, Sathya J, Swanson GP, Chen BE, Warde PR: Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110). *J Clin Oncol* 2012; 30(Suppl): Abst. 4509.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=93974

Other Participant(s): ECOG, NCCTG/Alliance, SWOG

Protocol(s): T94-0110

SWOG

Anderson K, Hartline J, Marrah D, Harris-Talley J, Klein E: Notifying study participants of increased prostate cancer risk due to vitamin E. American Society of Preventive Oncology Annual Meeting (ASPO), Washington, DC, Mar 2012.

Protocol(s): S0000

Goldkorn A, Ely B, Quinn DI, Tangen C, Tai Y-C, Twardowski P, Van Veldhuizen P, Agarwal N, Carducci M, Monk JP, Garzotto MG, Mack PC, Lara PN, Higano CS, Hussain M, Vogelzang N, Cote RJ, Thompson IM: Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421). *J Clin Oncol* 2012; 30(Suppl): Abst. 4663.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99395

Protocol(s): S0421

Guertin KA, Kristal AR, Arnold KB, Crowley J, Hartline J, Goodman G, Tangen C, Minasian L, Lippman S, Klein E, Casano PA: Effect of vitamin E and selenium on F2-isorostanes, an oxidative stress biomarker, and lung function. *Am J of Respiratory and Critical Care Medicine* 2012; 185(Meeting Abstracts): A6495.

http://ajrccm.atsjournals.org/cgi/reprint/185/1_MeetingAbstracts/A6495?sid=1590afe6-88da-4223-9a2d-46bc0368b7a4

Protocol(s): S0000

Hussain M, Tangen C, Higano C, Crawford E, Liu G, Wilding G, Prescott S, Akdas A, Small E, Dawson N, Donnelly B, Venner P, Vaishampayan U, Schellhammer P, Quinn D, Raghavan D, Vogelzang N, Thompson IM: Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. *J Clin Oncol* 2012; 30(Suppl): Abst. 4.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92516

Protocol(s): INT-0162

Lara PN, Ely B, Quinn DI, Tangen C, Gertz E, Hussain M, Vogelzang NJ, Thompson I, Van Loan M: SWOG 0421: Prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel (DOC) with or without atrasentan (ATR). *J Clin Oncol* 2012; 30(Suppl): Abst. 4547.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91416

Protocol(s): S0421

Lotan Y, Goodman P, Youssef R, Svatek R, Shariat SF, Tangen CM, Thompson IM, Klein EA: Evaluation of vitamin E and selenium on the prevention of bladder cancer in SWOG-coordinated SELECT. J of Urology 2012; 187(4 Suppl): Abst. 1273.

<http://www.jurology.com/article/S0022-5347%2812%2901967-2/fulltext>

Protocol(s): S0000

Moinpour C, Berry DL, Ely B, Tangen C, Higano C, Picus J, Schellhammer P, Skinner C, Cher M, Thompson I, Hussain M: Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)—Phase III. J Clin Oncol 2012; 30(Suppl): Abst. 4571.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101068

Protocol(s): INT-0162

Quinn D, Tangen C, Hussain M, Lara P, Goldkorn A, Garzotto M, Mack PC, Carducci M, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM: SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J Clin Oncol 2012; 30(Suppl): Abst. 4511.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99398

Protocol(s): S0421

Skinner E, Goldman B, Sakr W, Petrylak P, Lenz H, Lee CT, Wilson S, Lerner S, Tangen C, Thompson IM: SWOG S0353: Phase II trial of intravesical gemcitabine in patients with superficial bladder cancer with recurrence following 2 prior courses of BCG. J of Urology 2012; 187(4 Suppl): Abst. 1666.

<http://www.jurology.com/article/S0022-5347%2812%2901886-1/fulltext>

Protocol(s): S0353

Vickers AJ, Ankerst DP, Sjoberg D, Tangen CM, Goodman PJ, Thompson IM: The Prostate Cancer Prevention (PCPT) risk calculator and the relationship between PSA and biopsy outcome. J of Urology 2012; 187(4 Suppl): Abst. 1217.

<http://www.jurology.com/article/S0022-5347%2812%2901868-X/fulltext>

Protocol(s): SWOG-9217

Vogelzang N, Ely B, Fink LM, Goldkorn A, Tangen CM, Twardowski P, Van Velhuizen PJ, Agarwal N, Carducci M, Monk JP, Garzotto MG, Mack PC, Lara PN, Higano CS, Hussain M, Quinn DI, Cote RJ, Thompson IM: Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2012; 30(Suppl): Abst. 10503.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99469

Protocol(s): S0421

Gynecologic Cancer

GOG

Ng CS, Lee TY, Coleman RL, Zheng Z, Dunning B, L'Heureux D, Mannel RS, Lee S: ACRIN 6695 perfusion CT as prognostic imaging biomarker in ovarian cancer. *J Clin Oncol* 2012; 30(Suppl): Abst. TPS5114.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100631

Other Participant(s): ACRIN

Protocol(s): GOG-0262

NCIC Clinical Trials Group

Mackay H, Eisenhauer EA, Kamel-Reid S, Clarke B, Walsh W, Karakasis K, Salvesen HB, Oza AM: Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC). *J Clin Oncol* 2012; 30(Suppl): Abst. 5010.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98503

Other Participant(s): NCCTG/Alliance

Protocol(s): NCIC-160

SWOG

Coleman R, Moon J, Sood A, Branham D, Delmore J, Bonebrake A, Anderson G, Alberts D, Markman M: Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. *J Clin Oncol* 2012; 30(Suppl): Abst. 5015.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94269

Protocol(s): S0904

Head and Neck Cancer

ECOG

Marur S, Lee J, Cmelak AJ, Zhao WJ, Westra WH, Chung CH, Gillison ML, Gilbert J, Bauman JE, Wagner LI, Ferris RL, Trevarthen DR, Colevas AD, Jahagirdar BN, Burtness BA: ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). *J Clin Oncol* 2012; 30(Suppl): Abst. 5566.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97623

Protocol(s): E1308

Psyrris D, Lee J, Pectasides E, Vasilakopoulou M, Burtness BA, Rimm D, Wanebo HJ, Forastiere AA: Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC). *J Clin Oncol* 2012; 30(Suppl): Abst. 5576.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98666

Protocol(s): E2303

Kidney Cancer

ECOG

Balzer-Haas NS, Manola J, Ky B, Flaherty KT, Uzzo RG, Wood CG, Kane CJ, Jewett M, Atkins MB, Dutcher JJ, DiPaola RS: Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC). J Clin Oncol 2012; 30(Suppl): Abst. 4500.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94335

Protocol(s): E2805

Leukemia, Myelodysplasia, and Transplantation

CALGB/Alliance

Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngela DJ, Kolitz JE, Powell BL, Voorhees PM, Wang ES, Blum WG, Stone RM, Marcucci G, Bloomfield CD, Moser BK, Larson RA: A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. J Clin Oncol 2012; 30(Suppl): Abst. 6526.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=93923

Protocol(s): CALGB-10502

Beumer JH, Lewis LD, Owzar K, Jiang C, Holleran JL, Christner SM, Blum WG, Devine SM, Linker C, Larson RA, Ratain MJ, Egorin M: Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study. J Clin Oncol 2012; 30(Suppl): Abst. 2533.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96723

Protocol(s): CALGB-100103, CALGB-10503, CALGB-19808

COG

Angiolillo AL, Schore RJ, Winick NJ, Devidas M, Zheng HW, Wood C, Lane AR, Raetz EA, Carroll WL, Hunger SP: Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4. J Clin Oncol 2012; 30(Suppl): Abst. 9543.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97971

Protocol(s): AALL07P4

Asselin BL, Devidas M, Zhou T, Camitta BM, Lipshultz SE: Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL). J Clin Oncol 2012; 30(Suppl): Abst. 9504.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98077

Protocol(s): POG-9404

Baruchel S, Wu B, Mokhtari RB, Glade Bender JL, DuBois SG, Widemann BC, Park JR, Stempak D, Ahern CH, Weigel BJ: Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. *J Clin Oncol* 2012; 30(Suppl): Abst. 9502.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76045

Protocol(s): ADVL0413, ADVL0613, ADVL0714, ADVL0815

Dreyer ZE, Salzer WL, Jones T, Devidas M, Rodriguez V, Winick NJ, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Carroll WL, Hunger SP: Intensified Peg- Asparaginase In High Risk Acute Lymphoblastic Leukemia (HR-ALL): Children's Oncology Group (COG) AALL08P1. *Pediatr Blood Cancer* 2012; 58(7): Pg. 1065, Poster 653.

http://www.connect2conferences.com/aspho4/ws_search/index.php?task=detail&abstract_id=703&page=&back=L2FzcGhvNC93c19zZWfY Y2gvaW5kZXgucGhwP3Rhc2s9c2VhcmNoJmF1dGhvcnM9ZjJleWVv

Protocol(s): AALL08P1

Larsen EC, Raetz EA, Winick NJ, Salzer WL, Nachman JB, Devidas M, Hunger SP, Carroll WL: Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group study AALL0232. *J Clin Oncol* 2012; 30(Suppl): Abst. CRA9508.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99179

Protocol(s): AALL0232

Lau S, Balsamo L, Devidas M, Lu X, Winick NJ, Hunger SP, Carroll WL, Maloney KW, Kadan-Lottick NS: Family life events in the first year after diagnosis of standard risk (SR) acute lymphoblastic leukemia (ALL): A report from Children's Oncology Group (COG) AALL0331. *Pediatr Blood Cancer* 2012; 58(7): Pg. 1040, Poster 570.

http://www.connect2conferences.com/aspho4/ws_search/index.php?task=detail&abstract_id=731&page=&back=L2FzcGhvNC93c19zZWfY Y2gvaW5kZXgucGhwP3Rhc2s9c2VhcmNoJmF1dGhvcnM9QmFsc2Ftbw==

Protocol(s): AALL0331

Lindemulder SJ, Stork LC, Bostrom BC, Lu X, Devidas M, Neglia JP, Kadan-Lottick NS: Trends in body mass index (BMI) during and after treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG). *J Clin Oncol* 2012; 30(Suppl): Abst. 9546.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95983

Protocol(s): ALTE02C2

Myers R, Balsamo L, Carroll WL, Hunger SP, Winick NJ, Devidas M, Lu X, Maloney KW, Kadan-Lottick NS: Emotional and behavioral functioning in the first year after diagnosis of standard risk (SR) acute lymphoblastic leukemia (ALL): A report from Children's Oncology Group (COG) AALL0331. *Pediatr Blood Cancer* 2012; 58(7): Pg. 1040, Poster 568.

http://www.connect2conferences.com/aspho4/ws_search/index.php?task=detail&abstract_id=827&page=&back=L2FzcGhvNC93c19zZWfY Y2gvaW5kZXgucGhwP3Rhc2s9c2VhcmNoJmF1dGhvcnM9TXllcnM=

Protocol(s): AALL0331

Salzer WL, Jones T, Dreyer ZE, Gore L, Winick NJ, Sung L, Raetz EA, Devidas M, Carroll WL, Hunger SP, Hilden JM, Brown PA: Decreased Induction Morbidity And Mortality With Changes To Induction Therapy In Infants With Acute Lymphoblastic Leukemia Enrolled On Children's Oncology Group (COG) Trial AALL0631. *Pediatr Blood Cancer* 2012; 58(7): Pg. 1016, Abst. 409.

http://www.connect2conferences.com/aspho4/ws_search/index.php?task=detail&abstract_id=739&page=&back=L2FzcGhvNC93c19zZWfY Y2gvaW5kZXgucGhwP3Rhc2s9c2VhcmNoJmF1dGhvcnM9U2FsemVv

Protocol(s): AALL0631

Sorrell AD, Alonzo T, Gerbing RB, Berman JN, Meshinchi S, Taub JW, Hilden JM, Gamis AS: Remission Marrow Blast Percentage Predicts Relapse Risk In Children With Myeloid Leukemia Associated With Down Syndrome. *Pediatr Blood Cancer* 2012; 58(7): Pg. 1039, Poster 564.

http://www.connect2conferences.com/aspho4/ws_search/index.php?task=detail&abstract_id=580&page=&back=L2FzcGhvNC93c19zZWFiY2gvaW5kZXgucGhwP3Rhc2s9c2VhcmNoJmF1dGhvcnM9U29ycmVsbA==

Protocol(s): A2971

Sun D, Kaeding A, Magoon D, Jones T, Devidas M, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Dreyer ZE, Hunger SP, Hilden JM, Brown PA: Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631. *J Clin Oncol* 2012; 30(Suppl): Abst. 9548.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97124

Protocol(s): AALL0631

Tasian SK, Maude SL, Hall JW, Vincent T, Mullighan CG, Willman CL, Hunger SP, Loh ML, Teachey DT, Grupp SA: In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL). *J Clin Oncol* 2012; 30(Suppl): Abst. 9506.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98540

Protocol(s): P9906

SWOG

Nand S, Gundacker H, Godwin JE, Willman C, Norwood T, Erba H, Howard D, Coutre S, Othus M, Appelbaum F: A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol—Report on the good-risk patients. *J Clin Oncol* 2012; 30(Suppl): Abst. 6502.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=93704

Protocol(s): S0703

Lung Cancer

CALGB/Alliance

Shepherd FA, Bourredjem A, Brambilla E, Domerg C, Douillard J-Y, Filipits M, Graziano SL, Hainaut P, Janne PA, Le Chevalier T, Le Teuff G, Pignon J-P, Pirker R, Seymour L, Soria J-C, Taron M, Tsao MS: Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. *J Clin Oncol* 2012; 30(Suppl): Abst. 7007.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=93748

Other Participant(s): NCCTG/Alliance

Protocol(s): CALGB-150601, CALGB-150802, JBR10

Suk Heist RC, Wang X, Hodgson LD, Otterson GA, Stinchcombe TE, Socinski MA: CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 2012; 30(Suppl): Abst. 7513.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97765

Protocol(s): CALGB-30704

ECOG

Hanna NH, Dahlberg SE, Kolesar J, Hirsch FR, Ramalingam SS, Schiller JH: Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). *J Clin Oncol* 2012; 30(Suppl): Abst. 7516.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94015

Protocol(s): E4508

NCCTG/Alliance

Dy GK, Molina J, Qi Y, Ansari R, Thomas S, Ross HJ, Meyers J, Mandrekar S, Adjei AA: N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2). *J Clin Oncol* 2012; 30(Suppl): Abst. 7555.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96883

Protocol(s): N0821

Schild SE, Molina JR, Dy GK, Rowland KM, Sarkaria JN, Thomas SP, Northfelt DW, Kugler JW, Foster NR, Adjei AA: N0321: A phase II study of bortezomib, paclitaxel, carboplatin (CBCDA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 2012; 30(Suppl): Abst. 7073.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92750

Protocol(s): N0321

NCIC Clinical Trials Group

Fehringer G, Liu J, Pintilie M, Sykes J, Liu N, Cheng D, Chen Z, Seymour L, Der SD, Shepherd FA, Tsao M-S, Hung RJ: Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue. *Proc Am Assoc Cancer Res* 2012; 72(8 Suppl): Abst. 4210.

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/4210?sid=b6d06d6d-11fb-47ca-ad8c-ebfbc75e8eb8

Protocol(s): JBR10

SWOG

Allen J, Moon J, Gadgeel S, Kelly K, Mack PC, Saba H, Mohamed MK, Gandara D.: SWOG 0802: A randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC). *J Clin Oncol* 2012; 30(Suppl): Abst. 7005.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96718

Protocol(s): S0802

Garland L, Ou S-H, Moon J, Mack PC, Testa J, Tsao A, Wozniak A, Gandara D: SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). *J Clin Oncol* 2012; 30(Suppl): Abst. 7083.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98343

Protocol(s): S0722

Hesketh PJ, Redman M, Unger JM, Moon J, Gandara DR: Older patient participation in SWOG lung cancer trials: Comparative analysis from 1993 to 2008. J Clin Oncol 2012; 30(Suppl): Abst. 7570.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98771

Protocol(s): Multiple Trials

Mack P, Moon J, West H, Franklin W, Varella-Garcia M, Wynes M, Wozniak A, Redman M, Hirsch F, Gandara D: Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib and bevacizumab in never-smokers with advanced NSCLC. J Clin Oncol 2012; 30(Suppl): Abst. 7552.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96836

Protocol(s): S0636

West H, Moon J, Hirsch F, Mack P, Wozniak A, Lau D, Fehrenbacher L, Bury M, Redman M, Gandara D: SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). J Clin Oncol 2012; 30(Suppl): Abst. 7517.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97070

Protocol(s): S0635, S0636

Wozniak A, Moon J, Thomas CL, Kelly K, Mack PC, Gaspar LE, Raben D, Pandya KJ, Gandara DR: SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30(Suppl): Abst. 7018.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92505

Protocol(s): S0533

Lymphoma and Plasma Cell Disorders

CALGB/Alliance

Leonard J, Jung S, Johnson JL, Bartlett NL, Blum KA, Cheson BD: CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 2012; 30(Suppl): Abst. 8000.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=93509

Protocol(s): CALGB-50401

COG

Appel BE: Treatment of pediatric stage IA lymphocyte-predominant Hodgkin lymphoma with surgical resection alone: A report from the Children's Oncology Group. J Clin Oncol 2012; 30(Suppl): Abst. 9524.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94851

Protocol(s): AHOD03P1

Mosse YP: Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. J Clin Oncol 2012; 30(Suppl): Abst. 9500.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96905

Protocol(s): ADVL0912

ECOG

Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Tan KL, Gascoyne RD, Gordon LI, Horning SJ, Kahl BS, Ambinder RF: Plasma viral DNA as a marker of tumor response in EBV(+) Hodgkin lymphoma in a phase III study (E2496). J Clin Oncol 2012; 30(Suppl): Abst. 8003.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=93670

Protocol(s): E2496

Williams ME, Hong F, Kahl BS, Gascoyne RD, Wagner LI, Krauss JC, Horning SJ: A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. J Clin Oncol 2012; 30(Suppl): Abst. 8007.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98874

Protocol(s): E4402

SWOG

Persky DO, Bernstein SH, Goldman B, Rimsza LM, Fisher RI, Miller TP: A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520. J Clin Oncol 2012; 30(Suppl): Abst. E18536.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95371

Protocol(s): S0520

Press O, Unger J, LeBlanc M, Rimsza L, Friedberg J, Czuczman M, Kaminski M, Braziel R, Spier R, Maloney DG, Cheson BD, Miller T, Fisher R: A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models.. J Clin Oncol 2012; 30(Suppl): Abst. 8001.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95376

Protocol(s): S0016

Tan KL, Scott DW, Hong F, Horning SJ, Fisher RI, Bartlett NL, Shepherd L, Connors JM, Kahl BS, Gordon L, Steidl C, Gascoyne R: Tumor-Associated Macrophages Predict Inferior Outcomes in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – A Correlative Study from the E2496 Intergroup Trial. United States and Canadian Academy of Pathology, Vancouver, BC, Canada, Mar 2012. Abst. 1568.

http://www.abstracts2view.com/uscap12/view.php?nu=USCAP12L_1568

Protocol(s): E2496

Melanoma/Skin Cancers

ECOG

Kalinsky KM, Lee S, Lawrence DP, Iafrate AJ, Borger DR, Averbook BJ, Tarhini AA, Kirkwood JM: A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607). *J Clin Oncol* 2012; 30(Suppl): Abst. 8522.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95547

Protocol(s): E2607

SWOG

Flaherty LE, Moon J, Atkins MB, Tuthill RJ, Thompson JA, Vetto J, Haluska FG, Pappo A, Sosman JA, Redman B, Ribas A, Kirkwood J, Sondak V: Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. *J Clin Oncol* 2012; 30(Suppl): Abst. 8504.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92968

Other Participant(s): CALGB/Alliance, COG, ECOG

Protocol(s): S0008

Lao C, Moon J, Fruehauf J, Flaherty L, Bury M, Ribas A, Sondak V: SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. *J Clin Oncol* 2012; 30(Suppl): Abst. 8521.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95522

Protocol(s): S0826

Margolin K, Othus M, Gajewski T, Redman B, Chidiac T, Ribas A, Flaherty L, Sondak V: Phase II trial of RO4929097 Notch gamma-secretase inhibitor in metastatic melanoma: SWOG S0933. *J Clin Oncol* 2012; 30(Suppl): Abst. 8525.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97400

Protocol(s): S0933

Samlowski W, Moon J, Witter M, Atkins M, Kirkwood J, Othus M, Ribas A, Sondak V, Flaherty L: CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma. *J Clin Oncol* 2012; 30(Suppl): Abst. 8527.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96009

Other Participant(s): CALGB/Alliance, COG, ECOG

Protocol(s): S0008

Other Cancer

ACRIN

Muzi M, Opanowski A, Muzi JP, Obsekov G, Herman BA, Duan F, Doot RK, Siegal B, Mankoff D: Development of an advanced PET image analysis laboratory for the American College of Radiology Imaging Network. J Nucl Med 2012; 53(Suppl 1): Abst. 2308.

http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/53/1_MeetingAbstracts/2308

Protocol(s): 8029, ACRIN-6684, ACRIN-6687, RTOG-0837

CALGB/Alliance

Smith E, Pang H, Cirrincione CT, Fleishman SB, Paskett ED, Ahles TA, Fadul CE, Knox CR, Shapiro CL: CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN). J Clin Oncol 2012; 30(Suppl): Abst. CRA9013.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91721

Protocol(s): CALGB-170601

COG

Bagatell R: Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 2012; 30(Suppl): Abst. 9540.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99913

Protocol(s): ADVL0918

Fouladi M: A phase I trial of IMC A12 and temsirolimus in children with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 2012; 30(Suppl): Abst. 9541.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100412

Protocol(s): ADVL0813

ECOG

Fisch MJ, Zhao F, O'Mara A, Wang X, Cella D, Cleeland C: Determinants of fatigue improvement in outpatient oncology according to baseline categories of fatigue severity. J Clin Oncol 2012; 30(Suppl): Abst. 9112.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97311

Protocol(s): E2Z02

Manola J, Zhao F, Miller A, Pirl W, Wagner LI, Fisch MJ: Patterns of antidepressant use in cancer patients (pts): An analysis from SOAPP (ECOG E2Z02: Symptom Outcomes and Practice Patterns). J Clin Oncol 2012; 30(Suppl): Abst. 9016.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96804

Protocol(s): E2Z02

Patrick-Miller LJ, Zhao F, Cleeland C, Wagner LI, Fisch MJ, Mendoza TR: Validity and utility of the University of Texas M. D. Anderson Symptom Inventory (MDASI) among prostate cancer patients: Data from E2Z02: Symptom Outcomes and Practice Patterns (SOAPP). J Clin Oncol 2012; 30(Suppl): Abst. E15173.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98987

Protocol(s): E2Z02

Ritchie C, Manola J, Kvale E, Snyder C, Fisch MJ: The relationship between symptom burden and perceived comorbidity in outpatients with common solid tumors. J Clin Oncol 2012; 30(Suppl): Abst. 6080.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97052

Protocol(s): E2Z02

Wang XS, Zhao F, Fisch MJ, Mendoza TR, O'Mara A, Cella D, Cleeland C: Defining mild, moderate, and severe fatigue in cancer patients and survivors: E2Z02, a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2012; 30(Suppl): Abst. 9099.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96733

Protocol(s): E2Z02

Zhao F, Wagner LI, Pirl WF, Miller A, Fisch MJ: Racial disparities in depressive symptom prevalence and selective serotonin reuptake inhibitor (SSRI) utilization in cancer patients: An analysis from ECOG E2Z02: Symptom Outcomes and Practice Patterns (SOAPP). J Clin Oncol 2012; 30(Suppl): Abst. 6076.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96850

Protocol(s): E2Z02

NCCTG/Alliance

Atherton PJ, Halyard MY, Sloan JA, Miller RC, Deming RL, Tai THP, Stien KJ, Martenson JA: Patient assessment of measures of bowel function during and after pelvic radiation therapy: An ancillary study of North Central Cancer Treatment Group study N00CA. J Clin Oncol 2012; 30(Suppl): Abst. E16572.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99920

Protocol(s): N00CA

Barton DL, Liu H, Dakhil S, Linquist B, Sloan JA, Nichols TW, Stella PJ, Seeger GR, Loprinzi CL: Phase III evaluation of American ginseng (*panax quinquefolius*) to improve cancer-related fatigue: NCCTG trial N07C2. J Clin Oncol 2012; 30(Suppl): Abst. 9001.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94721

Protocol(s): N07C2

Chauhan C, Atherton PJ, Satele D, Dueck AC, Soori GS, Johnson DB, Mandrekar SJ, Buckner JC, Sloan JA: Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392). J Clin Oncol 2012; 30(Suppl): Abst. 6133.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101392

Protocol(s): N0392

Puttasavaiah S, Liu H, Qin R, Kottschade L, Barton D, Loprinzi C, Grothey A, Soori G, Sloan J: A comparison of simple single-item measures and the NCI Common Toxicity Criteria version 3.0 measure of peripheral neuropathy. *J Clin Oncol* 2012; 30(Suppl): Abst. 1557.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100961

Protocol(s): N04C7, N05C3

SWOG

Hartline J, Anderson K, Marrah D, Klein E: Challenges of collecting health data and maintaining contact with an aging study population. Society for Clinical Trials, Miami, FL, May 2012.

<http://www.sctweb.org/public/search/detail.cfm?ID=0F9295CC-0450-A16B-F7BC35B0726A45A3>

Protocol(s): S0000

Sarantopoulos J, Hoering A, Synold T, Mahalingam D, Wang D, Lenz H, O'Rourke P, Sexton R, Van Veldhuizen P, Mita M, El-Khoueiry AB, Chung V, Gandara D, Tejwan S, Takimoto C, Ivy P, Kurzrock R: Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutics committee study. *J Clin Oncol* 2012; 30(Suppl): Abst. 3078.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99141

Protocol(s): S0711

Stoermer K: Strategies to increase efficiency in protocol development. *J Clin Oncol* 2012; 30(Suppl 4): Abst. E16508.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100857

Protocol(s): Multiple Trials

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators

Carol H, Lock R, Maris J, Keir S, Gorlick R, Kolb A, Kang M, Reynolds P, Wu J, Kurmasheva R, Houghton P, Smith M: Pediatric Preclinical Testing Program (PPTP) evaluation of the JAK inhibitor AZD1480. *Proc Am Assoc Cancer Res* 2012; 72(8 Suppl): Abst. LB-318.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1ca1b018-6374-4e10-b351-ed4e89a1111b&cKey=61e3697d-d4d7-4813-9a65-c08fd712bdf8&mKey={2D8C569E-B72C-4E7D-AB3B-070BEC7EB280}>

Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Denicoff A, O'Mara AM, Rogak LJ, Clauser SB, Bryant DM, Gillis TA, Bearden JD, Siegel RD, Harness JK, Paul DB, Cleeland CS, Sloan JA, Schrag D, Minasian LM, Basch EM: Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *J Clin Oncol* 2012; 30(Suppl): Abst. 9047.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95239

Go RS, Zaren, H, Nair SG, Lanier KS, Thompson MA, Enos RA, Zhao J, Fleming DL, Leighton JC, Gribbin TE, Bryant DM, Carrigan A, Corpening JC, Csapo KA, Dimond EP, Ellison C, Gonzalez MM, Harr, JL, Wilkinson K, Denicoff A: Early-phase (EP) clinical trials (CTs) in the community: Results from the National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) Early-Phase Working Group (EPWG) Baseline Assessment Study (BAS). J Clin Oncol 2012; 30(Suppl): Abst. E16561.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96679

Masset H, Jaeckle KA, Hopkins JR, Mann BS, Denicoff A, Dilts DM: Intervention to increase site activations for multicenter trials to improve accrual. J Clin Oncol 2012; 30(Suppl): Abst. E16569.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94823

Mitchell SA, Lang K, Nichols C, Clauser SB, Federico V, Lalla D, Tripathy D, Hurvitz SA, Castro KM, Reeve BB, Rogak LJ, Denicoff A, Chen A, Piekarz R, Bennett AV, Atkinson TM, O'Mara AM, Minasian LM, Basch EM: Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer. J Clin Oncol 2012; 30(Suppl): Abst. 9144.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100819

Nichols C, Mitchell SA, Lang K, Federico V, Castro KM, Rogak LJ, Lalla D, Clauser SB, Reeve BB, Denicoff A, Chen AP, Piekarz R, Atkinson TM, Mayer M, Brammer MG, Sit L, O'Mara AM, Minasian LM, Basch EM: Acceptability of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women with metastatic breast cancer (MBC). J Clin Oncol 2012; 30(Suppl): Abst. E19633.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100924

Smith M, Keir S, Maris J, Kolb A, Reynolds P, Kang M, Carol H, Lock R, Gorlick R, Kurmasheva R, Billups C, Houghton P: Pediatric Preclinical Testing Program (PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK) inhibitor. Proc Am Assoc Cancer Res 2012; 72(8 Suppl): Abst. LB-317.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1ca1b018-6374-4e10-b351-ed4e89a1111b&cKey=302d20f8-8015-402e-8297-965ab6112618&mKey={2D8C569E-B72C-4E7D-AB3B-070BEC7EB280}>

Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References only appear under one disease heading and the Lead Cooperative Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the required information is available. Links to online abstracts are provided if they were available at the time of publication, but there is no guarantee that these links will remain active.